term follow-up Bone marrow transplantation (BMT) involving intensive conditioning with high doses of cytostatic agents and total body irradiation (TBI) may result in impaired pubertal development and a reduced final height (FH), by inducing multiple endocrinological disturbances, including growth hormone deficiency (GHD), and damage to the epiphyseal growth plates. [1] [2] [3] [4] [5] [6] [7] In addition, BMT is often superimposed on the preceding primary and relapse therapies, which may compromise pubertal development and FH in their own right. 8 The literature contains little information on pubertal development and FH after BMT, and practically no data on FH achieved in response to growth hormone (GH) replacement therapy. 9 We have performed autologous BMT since 1985 at our center, and have previously reported on the prepubertal growth in our group of children, a number of whom have now reached their FH. 10 These latter children have provided us with an opportunity to describe pubertal development in its entirety and to preclude the problems inherent in comparing growth in children who have reached different stages of development.
We present a longitudinal study of pubertal development and growth until FH in response to hormonal replacement therapy in a group of children treated with autologous BMT, including TBI, for ALL. The influence of GH treatment on long-term growth was of particular interest.
Patients and methods
Between October 1985 and March 1994, 30 children with ALL were treated with autologous (n ¼ 29) or syngeneic BMT (n ¼ 1), including TBI, at the University Hospital of Uppsala. In all, 11 children relapsed after BMT with a median time to relapse of 5 months (range 3-48 months). Two girls underwent BMT after the onset of puberty. In the present study, we included the 17 patients with a relapsefree survival after BMT, who underwent transplantation before or at the beginning of puberty (two boys in Tanner stage G2) and who had reached FH at the time of their last visit (Table 1) . Their median age at BMT was 8.3 years (range 3.6-13.1), and at the last visit it was 19.5 years (range 15.9-22.1). The children had received treatment according to the Swedish Child Leukemia Group protocol that applied at the time of diagnosis. 11 In addition to multiagent chemotherapy, seven children had received cranial irradiation (CI) before BMT at target doses ranging from 18 to 24 Gy (including the spine in one girl; patient no. 11, see Table 1 ). In five children with high-risk ALL, the CI was given as 'prophylaxis', and in two children it was given as treatment for a CNS relapse. Five boys with a testicular relapse received additional testicular irradiation at target doses ranging from 16 to 32 Gy. Details of the conditioning regimens have been thoroughly presented elsewhere. 12 Briefly, patients were conditioned with prednisone, teniposide, daunorubicin, vincristine, cyclophosphamide, and cytarabine plus TBI of 7.5 Gy in a single fraction with a midline dose rate of 0.15 Gy/min. The two children most recently undergoing transplantation (nos. 9 and 17) were treated with fractionated TBI, consisting of 12 Gy in six fractions over 3 days with a midline dose rate of 0.15 Gy/min.
The children were divided into two groups according to the radiation therapy. Group 1 consisted of 10 children (six boys) who had received TBI as part of the conditioning therapy before BMT. Group 2 consisted of the seven children (five boys) who, in addition to TBI, were given CI before BMT. The two children with a CNS relapse were scheduled to receive cytarabine intrathecally every sixth week until 2 years after BMT, but this treatment was discontinued after two courses in one child (no. 16), owing to severe headache. Otherwise, no further chemotherapy was given after BMT. One girl received corticosteroid treatment for 7 months after BMT, because of idiopathic pneumonia syndrome (no. 5).
Data on growth, pubertal status, and hormonal status were collected at our center as part of our ongoing prospective long-term follow-up program, which lasts until FH has been attained and always for a minimum of 10 years after BMT. All children were evaluated before BMT, 3, 6, 9, and 12 months after BMT, and then annually. No child was completely lost to follow-up, but one child abstained from the routine check-ups during puberty (no. 16). Onset of puberty was defined as a testicular volume X4 ml in boys or Tanner breast stage B2 in girls. 13 As irradiation may influence testicular volume, if other signs of pubertal development had occurred in boys while testicular volume had not reached 4 ml, puberty was considered to have begun on the basis of a combination of progression of Tanner stages and increasing levels of testosterone. When sex steroids were given, the time of onset of puberty was defined as the start of treatment with sex steroids. Testicular volume was assessed with an orchidometer, as described by Prader. 14 Height was measured with a Harpenden stadiometer. Height standard deviation scores (H-SDS) were calculated using a Swedish reference, according to the formula (actual heightÀmean height for age and sex)/standard deviation of height for age and sex. 15 To avoid the possible bias inherent in late puberty, H-SDS at the last prepubertal recording was determined by extrapolation from the childhood reference, using the model developed by Karlberg et al. 16 Short stature was defined as height o2 s.d. FH was considered to have been reached when the annual increase in height was less than 1 cm. Target height (TH) was calculated as (mother's height þ father's height713 cm)/2. Regular measurement of hormonal values using standard laboratory methods included (reference values given in parentheses): folliclestimulating hormone (FSH); (boys: 2-12 years of age 0.01-0.4 mg/l; during puberty 0.2-3.5 mg/l; adult men 0.2-2.1 mg/l, girls: 2-9 years of age 0.02-0.4 mg/l; 10-13 years of age 0.05-2.0 mg/l; post menarcheal women irrespective of menstrual phase 0.13-2.8 mg/l); luteinizing hormone (LH) Discontinued GH treatment after a few weeks.
Pubertal development and final height after autologous BMT P Frisk et al (boys: 2-12 years of age o0.1 mg/l; during puberty 0.1-2.0 mg/l; adult men 0.2-1.6 mg/l, girls: 2-9 years of age o0.05 mg/l; 10-13 years of age 0.01-2.0 mg/l; post menarcheal women irrespective of menstrual phase 0.1-15 mg/l), testosterone levels (adult men 10-45 nmol/l), and estradiol levels (post menarcheal women irrespective of menstrual phase 60-1300 pmol/l). Normal serum insulin-like growth factor (IGF)-1 values were 191-529 mg/l in both males and females 16-24 years of age. For the purpose of screening, spontaneous GH was scheduled to be measured annually until FH or start of GH treatment, by sampling blood every 30 min for 2 h after the subjects had fallen asleep (four point GH test). Excluding a boy who abstained from regular visits during puberty (no. 16), 82 of 101 (81%) scheduled four-point GH tests were performed (median five tests per patient, range 2-8). In addition, children with poor growth were scheduled for a 12-or 24-h secretion curve, for which blood was sampled every 30 min. The 12-h secretion curves were performed during the night. The cutoff level for diagnosis of GH deficiency (GHD) was considered to correspond to a peak level of 10 mg/l. Up to 1993, a radioimmunoassay was used, in which 10 mg/l corresponded to 20 mU/l. 10 Thereafter, GH (22 kDa) was measured by fluoroimmunoassay (Delfia hGH, Wallac), in which 10 mg/l corresponded to 24 mU/l. The cutoff level for the diagnosis of GHD was arbitrarily set at 24 mU/l during childhood and puberty, and at 10 mU/l when the FH had been reached based on the result of a 12-or 24-h secretion curve. 17 The decision to treat with GH was based on auxiological and biochemical data. The dosing of GH corresponded to 0.033 mg/kg body weight/day (0.1 IU/kg body weight/day). In girls, puberty was induced using increasing doses of ethinylestradiol (starting dose 0.15 mg/kg/day). In boys, intramuscular injections of testosterone were used (starting dose 25 mg every 4 weeks, which was gradually increased until the adult dose of 250 mg every 3-4 weeks was reached). In two boys, oral treatment with testosteroneundecanoate was used (starting dose 40 mg twice daily). In all, 12 children received thyroxine replacement after BMT.
Statistics
All data are reported as medians (range). Groups were compared with the Mann-Whitney U-test. Changes within groups were analyzed with the Friedman test when appropriate, followed by the Wilcoxon matched-pair test. Spearman's rank correlations were calculated in analyses of relationships between variables. Multiple regression analysis was performed to examine the contribution of factors considered pertinent to post BMT growth (sex, age at BMT, CI, and duration of GH treatment). Both P-values and 95% confidence intervals are presented for the partial regression coefficients in the regression model, otherwise only P-values are presented. The significance level was set at 5%. All calculations were made with SPSS 11.0.
Ethics
This study was approved by the Ethics Committee of the Medical Faculty, Uppsala University.
Results

Pubertal development
Boys. No additional testicular irradiation: Group 1 (ÀCI): Puberty started spontaneously within the normal age range in the three boys of group 1 (Table 1) . One boy (no. 1) had testosterone levels at the lower end of the normal range during follow-up. He received androgen replacement therapy from the age of 14.3 years, because he was not content with his pubertal development. The other two boys (nos. 7 and 8) had normal testosterone and LH levels. Puberty developed normally, as gauged from the progression of Tanner stages, and both had reached stage G5 and P5 at their last visit.
Group 2 ( þ CI): Puberty started spontaneously within the normal age range in the three boys of group 2. Two boys (nos. 13 and 14) received androgen replacement therapy from the ages of 15.7 and 15.3 years, respectively. The third boy (no. 16) abstained from regular visits during puberty. When he returned to our attention at the age of 18.5 years, he complained of fatigue and lack of sexual drive, and received androgen replacement therapy, although his level of testosterone was repeatedly within the normal adult range. This treatment resulted in more developed secondary sex characteristics and an increase in sexual drive.
Additional testicular irradiation:
Of the five boys of groups 1 and 2 who had received additional testicular irradiation, three underwent transplantation before the onset of puberty (nos. 3, 9, and 12). Puberty started spontaneously in pat. no. 9, but he later developed hypergonadotrophic hypogonadism and received androgen replacement therapy at the age of 15.4 years. In the other boys, puberty was induced at the ages of 14.3 and 13.9 years. In two boys (nos. 10 and 17), BMT was performed after the onset of puberty (Tanner stage G2). One of them (no. 17) developed hypergonadotrophic hypogonadism, and received androgen replacement therapy 3 years after BMT, at the age of 16.4 years. The other boy (no. 10) had sufficient levels of testosterone to complete a normal pubertal development, and had a low testosterone level only 8 years after BMT, and was given androgen replacement therapy at the age of 22.8 years.
Girls. Group 1 (ÀCI): One girl (no. 5) had a spontaneous onset of puberty. Her puberty progressed normally and she had her menarche at the age of 14.2 years. At menarche, FSH and LH were increased (17.2 and 5.5 mg/l, respectively), but eventually they decreased to normal levels. Puberty was induced in one girl (no. 6) at the age of 12.4 years, using increasing doses of ethinylestradiol. She had her menarche at the age of 13.7 years. In two girls (nos. 2 and 4), administration of a low dose of ethinylestradiol (5 mg) was given at the ages of 10.5 and 10.6 years, and was discontinued once they had achieved menarche at the ages of 12.6 and 12.8 years, respectively. Group 2 ( þ CI): The girl (no. 11) who had received craniospinal irradiation had an onset of puberty at the age of 9.6 years, and had her menarche 1 year later. At menarche, FSH and LH were elevated (11.6 and 3 mg/L, respectively). Owing to a concomitant short stature and low GH levels, the puberty was blocked for 1 year with a GnRH analogue while she was started on GH therapy. Puberty was induced in one girl (no. 15) using increasing doses of ethinylestradiol. Menarche occurred at the age of 13.6 years.
Final height
H-SDS at BMT, at the last prepubertal visit, and at attainment of FH are shown in Table 2 (which also includes TH-SDS and FH expressed in cm). The girl who received craniospinal irradiation was not included in the statistical analyses pertaining to growth.When the other patients were analyzed together (n ¼ 16), no significant difference was found between H-SDS at BMT and TH-SDS (À0.3 vs 0.1 s.d., P ¼ 0.38). There was a significant difference between H-SDS at FH and TH-SDS (P ¼ 0.001), and a significant decrease in H-SDS between BMT and FH (Po0.001), and between the last prepubertal visit and FH (Po0.001), but not between BMT and the last prepubertal visit (P ¼ 0.2) (the median time between BMT and the last prepubertal visit was 3.1 years in those who underwent transplantation before puberty). There was a significant decrease in H-SDS between BMT and FH and between FH and TH in both groups 1 and 2 when analyzed separately (Table 2) . No child had a height that was more than 2 s.d. below the mean at BMT. At FH, H-SDS was more than 2 s.d. below the mean for four children, three of whom had received CI and two of whom had suffered a CNS relapse. In univariate analyses (n ¼ 16), there was no significant correlation between age at BMT and height loss after BMT (BMT to FH) (r s ¼ 0.22, P ¼ 0.41), nor was there any significant difference in height loss after BMT between groups 1 and 2 (À1.1 vs À1.7 s.d., P ¼ 0.23), between boys and girls (À1.7 vs À0.8 s.d., P ¼ 0.054), or between those who had received GH and those who had not (À0.9 vs À1.7 s.d., P ¼ 0.22). A multiple regression analysis including all patients showed that young age at BMT, CI, and short duration of GH treatment, but not sex, were independent predictors of height loss after BMT (Table 3) . A second multiple regression analysis comprising only those who had received GH, but this time excluding sex as an independent variable, yielded similar results (here, only the influence of GH treatment is presented: B GH ¼ 0.24, P ¼ 0.049; 95% confidence interval 0.01-0.48).
Growth hormone
GH treatment was considered when the individual growth charts showed a clinically significant decrease in growth despite adequate thyroxine and sex hormone replacement. Of those patients not considered for GH treatment (n ¼ 5), peak GH in the four-point GH test was repeatedly 424 mU/l in three patients (nos. 2, 6 and 8) and o24 mU/l in two patients (nos. 1 and 7). Of those considered for GH treatment (n ¼ 12), seven children were tested with a 12-or 24-h secretion curve (median peak GH 9.8 mU/l). Six children were found to be GH deficient according to definition (Table 1) . Four children only had the four-point GH test; three children had peak GH value o24 mU/l and one child had a peak value of 27.2 mU/l (median peak GH 17.4 mU/l). One boy declined GH testing Table 2 Standard deviation score for height (H-SDS) and target height (TH)-SDS in 17 children treated with autologous BMT, including TBI, who had reached their final height In all, 10 children received TBI only (group 1) and six children received additional cranial irradiation (CI; group 2). One girl received craniospinal irradiation, and is presented separately.
Table 3
Multiple regression analysis of changes in standard deviation score for height between BMT and final height (FH)
Age at BMT (years) B age ¼ 0.13
R 2 of a model indicates how large a proportion of the total variation the model explains. B age , B ci , B sex , and B GH are the partial regression coefficients for the variables, age at BMT, cranial irradiation, sex, and duration of GH treatment. Both P-values and 95% confidence intervals are presented for the partial regression coefficients.
(no. 16). GH treatment was started in 11 of these 12 children; one boy (no. 10) with diagnosed GHD did not receive GH since the epiphyses were almost closed. Treatment was discontinued after a few weeks in patient no. 16, because of unexpected side effects manifested as aggressive behavior. Treatment was started at a median age of 12.4 years (11.0-14.4) in those who continued their treatment (n ¼ 10), and lasted for a median of 3.8 years (2.0-8.1). None developed any adverse effects requiring discontinuation of GH. One patient discontinued treatment due to poor response after 2 years. In the other patients, GH treatment was continued through to FH. Six patients were retested with a 24-h secretion curve, after having attained FH and discontinued GH treatment. The median peak GH in these patients was 14.8 mU/l (6.5-27.0). Four patients had peak GH levels 410 mU/L. One girl (no. 11) had a GH peak of 6.5 mU/l and one boy (no. 14) had a GH peak of 9.4 mU/l. We decided not to reinstitute GH in these patients, as well as in the four untested patients, since we judged that there was no clinical indication for treatment and their serum IGF-1 values were within the normal range for age.
Discussion
Pubertal development
Puberty started at a normal age in all boys not given additional testicular irradiation and in the boy given the lowest testicular boost of 16 Gy. All boys who had received additional testicular irradiation eventually developed hypergonadotrophic hypogonadism and received androgen replacement therapy, albeit only after a period of several years in the two boys undergoing BMT after the onset of puberty. This is in line with data indicating that the likelihood of Leydig cell damage is directly correlated with dose, but inversely correlated with age at treatment. 18 Four of six boys who had not received additional testicular irradiation also received androgen replacement therapy, which is a larger proportion than reported in similar studies. 1, 2, 6 Since two of these patients had testosterone levels above the lower reference limit and were treated on clinical rather than biochemical grounds, this probably reflects a more liberal treatment policy rather than more extensive Leydig cell damage.
In two girls, puberty was induced using increasing doses of ethinylestradiol. In another two, a low dose of ethinylestradiol was given during a limited time period, but was discontinued following the progression of a normal pubertal development. It should be emphasized that, in cases of hypogonadism, sex steroid therapy should be administered with caution in order to avoid premature epiphyseal fusion, which could result in a decreased FH. It has been reported that initially raised FSH levels in females may in fact return to normal, indicating the recovery of ovarial function. 19 
FH and GH
We found a significant decrease in H-SDS at FH relative both to H-SDS at BMT and to the genetic potential (TH-SDS). This decrease was significant both in those who had received TBI only and in those who had been given additional CI. The decrease occurred mostly during puberty, there being no significant loss in prepubertal height after BMT. The small number of patients with a long period of prepubertal growth may have prevented the detection of a significant decrease in height during the prepubertal years, however. Clement-De Boers et al 3 noted a decrease in H-SDS only during puberty, whereas Bakker et al 1 in addition found a decrease in prepubertal growth. The size of height loss in our patients is comparable to that reported in the few FH studies published to date (Table 4) . 1, 3, 4, 20, 21 Based on findings in 12-or 24-h GH profiles, GH deficiency was diagnosed in six children out of seven tested. GH deficiency after BMT has been reported in many studies, particularly after a combination of CI and TBI, but also after TBI alone. 6, 7, [21] [22] [23] Clement-De Boers et al 3 suggested that the radiation threshold required to induce GHD is 8 Gy, given in a single fraction. However, among our children given 7.5 Gy in a single fraction, three children without previous CI were found to be GH deficient. CI, young age at BMT, and short duration of GH treatment were independent predictors of height loss in our study. These retrospectively identified results are based on a small and heterogeneous sample and should be interpreted with caution. The findings are biologically plausible, however, and have to some extent been reported previously. A greater height loss with additional CI is probably caused by induction of a more profound GHD. 20, 21, 24 A greater height loss with young age at BMT may be explained by the fact that treatment at a younger age lengthens the post irradiation period. 1, 3, 4 Most studies on the effect of GH treatment after BMT have shown an increase in growth velocity over the first year of GH treatment as compared with the pretreatment velocity. This increase is smaller than that seen in children with idiopathic GHD, which is probably caused by the bone lesions induced by TBI. 5, 22, 23 The short-term growth response provides little help in predicting future growth and Table 4 Changes in standard deviation score for height between BMT and FH in six studies DH-SDS, changes in standard deviation score for height; sTBI, total body irradiation given in one fraction; fTBI, fractionated total body irradiation; CI, cranial irradiation. a Includes both patients who received TBI only (n ¼ 6)and those given additional cranial irradiation (n ¼ 8). b A total of 18 individuals had reached FH.
FH, however. We found a beneficial effect of GH treatment on growth up to FH, a finding not previously reported, although Cohen et al 4 found a trend towards better growth in their GH-treated subjects. Based on our results, we believe it to be a reasonable policy to administer GH to those children with a decreased growth rate and low GH values, presuming that other hormones necessary for optimal growth are adequately replaced. However, it must be emphasized that the reliability of the findings of this small study are limited and larger long-term studies are necessary to determine the ultimate benefit of GH therapy on growth after BMT.
